Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.6K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.6K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

9
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
9
Intracellular Signaling Cascades01:24

Intracellular Signaling Cascades

53.8K
Once a ligand binds to a receptor, the signal is transmitted through the membrane and into the cytoplasm. The continuation of a signal in this manner is called signal transduction. Signal transduction only occurs with cell-surface receptors, which cannot interact with most components of the cell, such as DNA. Only internal receptors can interact directly with DNA in the nucleus to initiate protein synthesis. When a ligand binds to its receptor, conformational changes occur that affect the...
53.8K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

18
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
18
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

17
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
17
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

9
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
9

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response to Letter to the Editor for "Boarding and Overcrowding are Facts of Life. It's Time We Adapt Resident Education to Them".

Annals of emergency medicine·2026
Same author

Preformulated, Shelf-Stable, Dendritic Cell-Targeting Nanogel mRNA Vaccine Delivery Platform.

Bioconjugate chemistry·2026
Same author

Synthesis, structure-activity relationships, and SARS-CoV-2 antiviral activity of 3,5-disubstituted isothiazolo[4,3-<i>b</i>]pyridines as PIKfyve inhibitors.

Frontiers in chemistry·2026
Same author

Scalable single-cell total RNA sequencing unifies coding and noncoding transcriptomics.

Nature biotechnology·2026
Same author

PIP4K2C: an emerging fulcrum for multiple diseases.

Nature reviews. Drug discovery·2026
Same author

Boarding and Crowding Are Facts of Life. It's Time We Adapt Resident Education to Them.

Annals of emergency medicine·2026

Related Experiment Video

Updated: Feb 16, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

Combating Intracellular Pathogens with Repurposed Host-Targeted Drugs.

Stanford Schor1, Shirit Einav1

  • 1Department of Medicine, Division of Infectious Diseases and Geographic Medicine, and Department of Microbiology and Immunology, School of Medicine, Stanford University , 300 Pasteur Drive, Lane Building Rm L127, Stanford, California 94305, United States.

ACS Infectious Diseases
|January 4, 2018
PubMed
Summary

Repurposing approved drugs offers a faster, broader approach to fighting intracellular pathogens. This strategy targets host cells, providing new therapies against diverse viral, bacterial, and protozoan infections.

More Related Videos

Single Cell Measurements of Vacuolar Rupture Caused by Intracellular Pathogens
10:39

Single Cell Measurements of Vacuolar Rupture Caused by Intracellular Pathogens

Published on: June 12, 2013

14.1K
Infection of Zebrafish Embryos with Intracellular Bacterial Pathogens
11:18

Infection of Zebrafish Embryos with Intracellular Bacterial Pathogens

Published on: March 15, 2012

44.6K

Related Experiment Videos

Last Updated: Feb 16, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Single Cell Measurements of Vacuolar Rupture Caused by Intracellular Pathogens
10:39

Single Cell Measurements of Vacuolar Rupture Caused by Intracellular Pathogens

Published on: June 12, 2013

14.1K
Infection of Zebrafish Embryos with Intracellular Bacterial Pathogens
11:18

Infection of Zebrafish Embryos with Intracellular Bacterial Pathogens

Published on: March 15, 2012

44.6K

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Global health faces a significant need for new treatments against intracellular pathogens.
  • Developing novel antimicrobials is costly, time-consuming, and often pathogen-specific.
  • Repurposing existing drugs targeting host functions is a promising alternative strategy.

Discussion:

  • This review explores drug repurposing for host-targeted, broad-spectrum treatments against intracellular pathogens.
  • Strategies involve targeting host cell factors essential for viral, bacterial, and protozoan infections.
  • Modulating host immune responses is also a key aspect of these repurposed therapies.

Key Insights:

  • Drug repurposing provides a viable pathway to develop broad-spectrum agents.
  • Host-targeted approaches overcome limitations of narrow-spectrum, pathogen-specific drugs.
  • This strategy addresses both current and emerging intracellular microbial threats.

Outlook:

  • Continued research into drug repurposing can accelerate therapeutic development.
  • Expanding the scope of host targets may yield novel treatment combinations.
  • Successful repurposing efforts can significantly impact global health by providing accessible countermeasures.